Search results for "Bladder Cancer"

showing 10 items of 211 documents

Urine cytology, tumour markers and bladder cancer

1998

MalePathologymedicine.medical_specialtyUrologyUrineAntigens NeoplasmBiomarkers TumorHumansMedicineAcidic Fibroblast Growth FactorGrowth SubstancesUrine cytologyCarcinoma Transitional CellBladder cancerUrinary bladdermedicine.diagnostic_testbusiness.industryMedical screeningmedicine.diseaseTumor associated antigenmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsBlood Group AntigensFemaleHistopathologybusinessBJU International
researchProduct

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation.

2014

Background: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. Methods: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach’s alpha.…

MalePsychometricsAparell urinariSurveys and QuestionnairesProspective cohort studyCàncermedia_commonLanguageCognitionGeneral MedicinePatient outcomeControl de qualitatNeoplasias de la Vejiga UrinariaEstudios de ValidaciónPsicometríaBufeta -- CàncerFemalePsicometriaClinical psychologyCross-Cultural ComparisonQuality of lifemedicine.medical_specialtyPsychometricsUrinary bladder neoplasms:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychological Tests::Psychometrics [Medical Subject Headings]:Publication Characteristics::Study Characteristics::Validation Studies [Medical Subject Headings]Cronbach's alpha:Disciplines and Occupations::Social Sciences::Quality of Life [Medical Subject Headings]medicine:Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms [Medical Subject Headings]media_common.cataloged_instanceHumansEuropean UnionEuropean unionAgedNeoplasm StagingGynecologyAnalysis of VarianceBladder cancerbusiness.industryResearchPublic Health Environmental and Occupational HealthConstruct validityTranslatingmedicine.diseaseCross-cultural studiesUnited StatesValidation studiesPatient outcomesCalidad de VidabusinessHealth and quality of life outcomes
researchProduct

ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion.

2012

Context: A summary of the 2nd International Consultation on Bladder Cancer recommendations on the reconstructive options after radical cystectomy (RC), their outcomes, and their complications. Objective: To review the literature regarding indications, surgical details, postoperative care, complications, functional outcomes, as well as quality-of-life measures of patients with different forms of urinary diversion (UD). Evidence acquisition: An English-language literature review of data published between 1970 and 2012 on patients with UD following RC for bladder cancer was undertaken. No randomized controlled studies comparing conduit diversion with neobladder or continent cutaneous diversion…

MaleReoperationmedicine.medical_specialtyUrologymedicine.medical_treatmentUrinary BladderRenal functionContext (language use)Controlled studiesUrinary DiversionCystectomyCystectomyUreterosigmoidostomyMedicineHumansBladder cancerbusiness.industryUrinary retentionUrinary diversionUrinary Reservoirs ContinentRecovery of Functionmedicine.diseaseSurgeryTreatment OutcomeUrinary IncontinenceUrinary Bladder NeoplasmsQuality of LifeFemalemedicine.symptombusinessEuropean urology
researchProduct

High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study

2018

The aim of this multicenter study was to investigate the prognostic impact of residual T1 high-grade (HG)/G3 tumors at re-transurethral resection (TUR of bladder tumor) in a large multi-institutional cohort of patients with primary T1 HG/G3 bladder cancer (BC).

MaleTime Factorsmedicine.medical_treatment:Medicina Básica [Ciências Médicas]Treatment outcomeBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumor; Aged; Aged 80 and over; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Progression-Free Survival; Recurrence; Regression Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineRecurrenceHigh-grade80 and overAged 80 and overTransurethral resection of bladder tumorCARCINOMA TRANSITIONAL CELLHigh riskBladder cancerFollow up studiesMiddle AgedPrognosisProgression-Free Survival3. Good healthScholarshipTreatment OutcomeLocal030220 oncology & carcinogenesisCiências Médicas::Medicina BásicaUrinary Bladder NeoplasmDisease ProgressionRegression AnalysisUrologic Surgical ProceduresFemaleSecond look resectionHumanmedicine.medical_specialtyTime FactorPrognosiUrologyBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumorCystectomyRegression AnalysiDisease-Free SurvivalResectionFollow-Up StudieCystectomy03 medical and health sciencesbladder cancer; high risk; high-grade; second look resection; transurethral resection of bladder tumor; aged; aged 80 and over; carcinoma transitional cell; cystectomy; disease progression; disease-free survival; female; follow-up studies; humans; malemedicineHumansProgression-free survivalAgedCarcinoma Transitional CellScience & Technologybusiness.industryGeneral surgeryDisease progressionCarcinomaNeoplasm RecurrenceUrinary Bladder NeoplasmsUrologic Surgical ProcedureTransitional CellTransurethral resection of bladder tumor.Neoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens

2014

To evaluate the concordance and prognostic role of histologic variants of bladder urothelial carcinoma in transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) specimens. METHODS Clinicopathologic information available at the time of RC and follow-up data from 4110 RC specimens, collected between January 2000 and December 2009 at 17 tertiary referral centers were retrospectively analyzed and evaluated for the presence or absence of uncommon variants of bladder urothelial carcinoma. The presence or absence of uncommon variants of bladder urothelial carcinoma was evaluated on previous TURBT specimens of patients undergoing RC. Cox regression was used to assess the impac…

MaleURINARY-BLADDER; CANCER; UPDATE; IMPACT; DIFFERENTIATIONIMPACTmedicine.medical_treatmentKaplan-Meier EstimateSettore MED/24 - UrologiaRetrospective StudieBladder cancer histologic variantsbladder urothelial carcinomaUrinary bladderMedicine (all)Middle AgedPrognosisCANCERDIFFERENTIATIONmedicine.anatomical_structureTreatment OutcomeUrinary Bladder Neoplasmbladder cancerFemaleHumanmedicine.medical_specialtyPrognosiConcordanceUrologyUrinary BladderUrologyCystectomyDisease-Free SurvivalFollow-Up StudieCystectomymedicineCarcinomaHumansClinical significanceAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urology; Medicine (all)Proportional Hazards ModelsRetrospective StudiesAgedBladder cancerProportional hazards modelbusiness.industryCarcinomaAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder NeoplasmsCancermedicine.diseaseUrinary Bladder NeoplasmsProportional Hazards ModelUPDATEURINARY-BLADDERbusinessFollow-Up Studies
researchProduct

The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemother…

2017

Background: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH. Methods: Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible. Those with incomplete or miscoded data were excluded. Khorana scores were calculated based on the pretreatment data and categorized into high (≥3) or intermediate (1-2) VTE risk. Other patient-, tumor-, and therapy-related factor…

MaleUrologic Neoplasmsmedicine.medical_specialtyMetastatic Urothelial Carcinomamedicine.medical_treatmentvenous thromboembolismAntineoplastic AgentsKhorana score030204 cardiovascular system & hematologyUrologic NeoplasmschemotherapyGastroenterologyArticleLeukocyte Count03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPredictive Value of TestsRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesLeukocytosisNeoplasm MetastasisAgedRetrospective StudiesChemotherapyBladder cancerbusiness.industryCancerRetrospective cohort studyHematologyGeneral MedicineMiddle Agedequipment and suppliesmedicine.disease3. Good healthSurgeryleukocytosisCardiovascular Diseases030220 oncology & carcinogenesisPredictive value of testsbladder cancerFemaleUrotheliummedicine.symptombusinessClinical and Applied Thrombosis/Hemostasis
researchProduct

The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications

2021

Tumor infiltrating lymphocytes (TIL) therapy was shown to provide durable objective response in patients with metastatic melanoma. As a fundamental first step to bring TIL therapy to clinical use, identification of patients whose tumors yield optimal numbers of reactive TIL is indispensable. We have previously shown that expansion of tumor reactive TIL from primary bladder tumors and lymph node metastases is feasible. Here, we performed TIL harvesting from additional surgical specimens (additional 31 primary tumors and 10 lymph nodes) to generate a heterogenous cohort of 53 patients with bladder cancer (BC) to evaluate the tumor characteristics that lead to tumor-reactive TIL expansion. Amo…

Malelcsh:Immunologic diseases. AllergyCD3Immunologychemical and pharmacologic phenomenaBacillus Calmette–GuerinLymphocyte ActivationCancer VaccinesImmunotherapy AdoptiveCohort StudiesBasal (phylogenetics)Tumor Necrosis Factor Receptor Superfamily Member 9Lymphocytes Tumor-InfiltratingmedicineImmunology and AllergyHumansadoptive cellular immunotherapyLymph nodeCells CulturedAgedCell ProliferationOriginal Researchmolecular subtypesBladder cancerbiologyTumor-infiltrating lymphocytesbusiness.industryhemic and immune systemsMiddle Agedmedicine.diseaseMycobacterium bovismedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic Metastasistumor-infiltrating lymphocytesCancer researchbiology.proteinInterleukin-2bladder cancerFemaleLymphAntibodyUrotheliumbusinesslcsh:RC581-607CD8Frontiers in Immunology
researchProduct

Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain : a multicenter observational study

2017

Objective We performed a cohort study in seven hospitals in Spain to determine the clinical characteristics of incident patients with bladder cancer, the diagnostic process, and the conditions that might affect health care interval times. Results 314 patients with bladder cancer were included, 70.3 (Standard Deviation [SD] 11.2) years old and 85.0% male. Clinical stage was T1 in 45.9% of patients. The median interval time between first consultation and diagnosis was of 104.0 days (Inter quartile range [IQR]:112.0; range from 0 to 986), being shorter for those patients who attended a hospital for their first consultation. The median interval time between diagnosis and first treatment was of …

Malemedicine.medical_specialty030232 urology & nephrologylcsh:MedicineGeneral Biochemistry Genetics and Molecular BiologyCohort Studies03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineObservational studyTumor stageHealth careDiagnostic techniques and proceduresmedicineUrinary bladder neoplasmHumansStage (cooking)lcsh:Science (General)lcsh:QH301-705.5AgedAged 80 and overBladder cancerbusiness.industryTime factorslcsh:RGeneral MedicineMiddle Agedmedicine.diseaseResearch Notelcsh:Biology (General)Urinary Bladder NeoplasmsSpain030220 oncology & carcinogenesisCohortNeoplasm stagingObservational studyFemaleBufeta -- CàncerbusinessCohort studylcsh:Q1-390
researchProduct

Postoperative complications and 90-day mortality in radical cystectomy in high-risk patients: A monocentric retrospective observational study.

2018

Aim: Assessing the incidence of immediate postoperative complications and 90-day mortality in high-risk patients who have undergone radical cystectomy; evaluating the correlation between preoperative conditions and surgery outcomes. Materials and methods: This is a monocentric retrospective observational study in which data of 65 patients have been analyzed. High-risk criteria: (a) Age ≥75 years, (b) obesity, (c) age-adjusted Charlson Comorbidity Index ≥8, (d) anemic status, and (e) pT ≥3. More than 50% of patients had two or more “high-risk” indicators. Postoperative complications were assessed through Clavien–Dindo classification. Results: Average age of patients was 70.4 years, average a…

Malemedicine.medical_specialtyClavien-Dindo ClassificationTime Factorsmedicine.medical_treatment030232 urology & nephrologyCystectomyRisk AssessmentSettore MED/24 - UrologiaCystectomy03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHumansRisk factorAgedRetrospective Studiesbusiness.industryMortality rateIncidence (epidemiology)Retrospective cohort studyGeneral MedicineOdds ratioMiddle AgedSurgeryUrinary Bladder Neoplasms030220 oncology & carcinogenesisRadical cystectomy bladder cancer Clavien–Dindo classification complications and mortalityFemalebusinessBody mass indexUrologia
researchProduct

Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral…

2020

Objectives: The aim of this multicenter study was to investigate the prognostic role of type 2 diabetes mellitus (T2DM) comorbidity in a large multi-institutional cohort of patients with primary T1HG/G3 non–muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB). Materials and methods: A total of 1,172 patients with primary T1 HG/G3 who had NMIBC on re-TURB and who received adjuvant intravesical bacillus Calmette-Guérin therapy with maintenance were included. Endpoints were recurrence-free survival and progression-free survival. Results: A total of 231 (19.7%) of patients had T2DM prior to TURB. Five-year recurrence-free survival estimates were 12.5…

Malemedicine.medical_specialtyDiabetes mellituUrologymedicine.medical_treatment030232 urology & nephrologyUrologyCystectomyResection03 medical and health sciences0302 clinical medicineDiabetes mellitusHigh gradeAdjuvants ImmunologicUrethraRecurrenceDiabetes mellitusmedicineHumansIn patientNeoplasm InvasivenessAgedNeoplasm StagingRetrospective StudiesBladder cancerProgressionbusiness.industryHigh riskBladder cancerType 2 Diabetes MellitusMiddle Agedmedicine.diseasePrognosisComorbidityProgression-Free Survival3. Good healthBladder cancer; Diabetes mellitus; High grade; High risk; Progression; RecurrenceSettore MED/24OncologyDiabetes Mellitus Type 2Urinary Bladder NeoplasmsChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineFemaleNeoplasm GradingbusinessAdjuvantUrologic oncology
researchProduct